Table 1.
Demographics and clinical characteristics of cases and controls receiving outpatient parenteral antimicrobial therapy
| Characteristic | Healthcare utilisation (HCU) (n = 63) | No HCU (N = 126) | P-value |
|---|---|---|---|
| Age, median (IQR) | 59 (50, 66) | 57 (47, 65) | 0.73 |
| Male sex | 42 (67) | 81 (64) | 0.75 |
| Body mass index (kg/m2) | 27 (23, 32) | 29 (25, 34) | 0.17 |
| Race | 0.54 | ||
| African American | 10 (16) | 19 (15) | |
| Caucasian | 49 (78) | 104 (83) | |
| Other | 4 (6) | 3 (2) | |
| Insurance | |||
| Medicare | 24 (38) | 50 (40) | 0.45 |
| Medicaid | 17 (27) | 42 (33) | |
| Private | 20 (32) | 33 (26) | |
| Not Insured | 2 (3) | 1 (1) | |
| Support status | 0.46 | ||
| Lives alone, no support | 8 (13) | 15 (12) | |
| Lives alone, has support | 17 (27) | 47 (37) | |
| Lives with adult | 37 (59) | 60 (48) | |
| Missing | 1 (2) | 4 (3) | |
| Discharge of care | 0.40 | ||
| Home | 40 (63) | 72 (57) | |
| Facilitya | 23 (37) | 54 (43) | |
| Charlson comorbidity index, median (IQR) | 3 (1, 5) | 3 (1, 4) | 0.41 |
| HCU | |||
| Prior admissions in past 12 months median (IQR) mean ± s.d. | 1 (0, 1) 1 ± 1.7 | 0 (0, 1) 0.7 ± 1.0 | 0.05 |
| History of drug-resistant organismb | 10 (16) | 10 (8) | 0.09 |
| Immunosupressedc | 9 (14) | 14 (11) | 0.53 |
| Infectious disease consult | 48 (76) | 100 (79) | 0.62 |
| Oral antibiotic in addition to intravenous | 12 (19) | 19 (15) | 0.49 |
| Length of stay, days, median (IQR) | 8 (6, 13) | 8 (6, 11) | 0.71 |
IQR, interquartile range, MRSA, methicillin-resistant S. aureus; VRE, vancomycin-resistant Enterococcus; ESBL, extended spectrum beta-lactamase; KPC, Klebsiella pneumoniae carbapenemase.
Data are presented as N (%) and median (IQR) unless otherwise specified.
a
Includes rehabilitation, skilled nursing facility and other.
b
Within 12 months of index discharge and includes MRSA, VRE, ESBL-producing organism, KPC-producing organism.
c
Includes a history of bone marrow transplant, solid organ transplant, malignancy or HIV/AIDS.